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SUMMARY
Between October and December 2005, 16 cases of wound botulism were notified to the health
authorities of North Rhine-Westphalia, Germany. All patients were injecting drug users (IDU)
and the epidemiological investigations suggested contaminated injection drugs as the most
probable source of infection. Clostridium botulinum was cultivated from clinical samples of six
patients and molecular typing revealed that the different isolates were clonally identical. Two
samples of heroin, one of them provided by a patient, were examined but C. botulinum could not
be isolated. This outbreak demonstrates that IDU are at risk for acquiring wound botulism by
injecting contaminated drugs. A greater awareness of this disease is needed by physicians and a
close cooperation between public health authorities, street workers, operators of sheltered
injecting facilities, and medical centres focusing on IDU is essential to prevent and manage
outbreaks in IDU in a timely manner.
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INTRODUCTION
Botulism is a rare disease, caused by neurotoxin re-
lease from the anaerobic spore-forming bacteria
Clostridium botulinum. Three main, naturally occur-
ring epidemiological types of botulism can be dis-
tinguished: foodborne, intestinal colonization (infant
form) and wound botulism. In Germany, botulism is
a notifiable disease. Between 2001 and 2004, 33 cases
of botulism were notified to the German health auth-
orities (6–11 per year) of which 29 were considered to
be foodborne in adults, three were infant botulism,
and one wound botulism [1].
In the days leading up to 3 November 2005, nine
cases of wound botulism in injecting drug users (IDU)
were notified in North Rhine-Westphalia (NRW). An
investigation was initiated to identify the extent and
the source of the outbreak in order to prevent the
occurrence of more infections. In this paper we de-
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paralysis or cranial nerve palsies, from 1 October 2005
onwards. Once their clinical condition allowed,
patients who gave informed consent were interviewed
by health authority personnel or trained social workers
with a detailed standardized questionnaire containing
questions on clinical symptoms, consumption of food
known to bear a risk for transmission of botulism,
drug-consumption habits during the 4 weeks prior to
hospital admission, and whether the patients knew
about other cases. Patients were also asked whether
they bought their heroin in Germany or in the adjac-
ent Netherlands and whether they knew from which
country or region the heroin originated.
On 14 November 2005 a message was circulated to
all public health departments and emergency phys-
icians in NRW via email networks maintained by the
Institute for Public Health, NRW and the local public
health departments ofNRW.Via theGerman national
Epidemiological Bulletin physicians and public health
authorities in other German federal states were in-
formed about the occurrence of wound botulism in
IDU in NRW [2, 3]. Through organizations offering
outreach, sheltered injecting facilities, and via street
workers attempts were made to inform the drug-using
communities in Germany about the clinical symptoms
of botulism as well as possible routes for acquiring
the disease. IDU were asked to seek medical advice if
symptoms (flaccid paralysis, difficulties in swallowing,
blurred vision) were present. Physicians and labora-
tories were reminded to immediately notify any cases
of botulism.
Due to possible cross-border spread of the out-
break, information was also distributed through the
European Early Warning and Response System as
well as Eurosurveillance [4].
Laboratory investigation
Wound swabs obtained from six patients were sent
to the National Reference Laboratory for Anaerobes
(NRL-A) for further identification.
As illicit injection drugs were the most strongly
suspected source of infection, patients were asked for
samples of heroin they were using in order to investi-
gate it for contamination with Clostridium spores.
Culture and identification of clinical samples
At NRL-A wound swabs were analysed employing
Columbia agar (Oxoid Ltd, UK) supplemented with
5% sheep blood (Oxoid GmbH, Germany), vitamin
K1 (Sigma Chemical Co., USA), and haemin (Serva
Feinbiochemica, Germany), as well as standard ap-
propriate supplemented broth media under anaerobic
conditions to cultivate anaerobes. Standard appro-
priate solid und broth media were used for aerobic
cultures to control possible aerobe growth. The an-
aerobic cultures were incubated in an anaerobic
chamber (Heraeus, Germany) containing 80% N2,
15% CO2 and 5% H2 at 37 xC. Obligate anaerobic
strains were identified by the Rapid ID 32A system
(bioMérieux, France) and by using pre-reduced an-
aerobic systems (PRAS; Anaerobe Systems, USA).
Cultivation of heroin samples
Two heroin samples were evaluated for micro-
biological culture. The samples were divided into
several aliquots and thereafter added to brain heart
infusion broth (Oxoid Ltd) supplemented with vit-
amin K1 and haemin. Samples were either untreated
or heat-shocked and incubated at 36 xC for 3 weeks
under aerobic and anaerobic conditions. Subcultures
were performed on days 7, 14, and 21 or after visible
growth on appropriate agar plates as described above
and incubated under aerobic and anaerobic con-
ditions.
Characterization and comparison of isolates
16S rDNA amplification was performed with the
primers 609V and 699R as described by Ackermann
et al. [5] resulting in a PCR product of y300 bp.
Amplification sequences were compared using the
NCBI BLAST database (http://www.ncbi.nlm.nih.
gov/blast/Blast.cgi).
For PCR, DNA was prepared using the Qiagen
tissue kit (Qiagen GmbH, Germany) according to the
manufacture’s instructions. PCR assays were separ-
ately performed for C. botulinum type A, B, E, and F
neurotoxin genes with the specific primers AS-11 and
AS-22 (toxin type A; sequences described by Takeshi
et al. [6]) to produce a PCR product of y283 bp and
the specific primers CBMLB1, CBMLB2, CBMLE1,
CBMLE2, CBMLF1, and CBMLF2 (toxin types B,
E, and F; sequences described by Lindström et al. [7])
to produce a PCR product ofy205 bp (toxin type B),
389 bp (toxin type E), and 543 bp (toxin type F). After
2 min of denaturation at 95 xC, 35 cycles of the PCR
mix with a final volume of 50 ml were run as follows:
30 s at 94 xC, 30 s at 55 xC for toxin types B, E, and F,
and 30 s at 53 xC for toxin type A, respectively, 1 min
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at 72 xC and a final extension cycle of 3 min at 72 xC.
C. botulinum reference strains (REB 1750, toxin type
A; REB 89, toxin type B; REB 1072, toxin type E;
and REB 1718, toxin type F) were used as control for
each toxin type.
For the antibiogram the susceptibility of the isolates
to penicillin, clindamycin, piperacillin/tazobactam,
imipenem, andmetronidazolewas determined byEtest
(AB Biodisk, Sweden), performed according to the
manufacturer’s instructions [8].
Serum samples from eight patients were tested in
bioassays on mice. Briefly, 0.5 ml serum of a patient
with suspected wound botulism was administered in-
traperitoneally to two mice. In the control group of
two other mice, each was initially administered in-
traperitoneally 0.5 ml antitoxin (Botulism Antitoxin
Behring; 1 ml contains : 750 IU C. botulinum type A
antitoxin, 500 IU C. botulinum type B antitoxin,
50 IU C. botulinum type E antitoxin ; Chiron Behring
GmbH & Co., Germany) followed by 0.5 ml serum of
the patient 30 min later. The mice were observed until
day 7 post-injection for survival and clinical signs of
botulism.
PFGE was performed by contour-clamped hom-
ogenous electric field electrophoresis (CHEF-DR III
apparatus; Bio-Rad, Germany) using the GenePath
Group 1 Reagent kit (Bio-Rad Laboratories, USA)
according to the protocol described previously for
the GenePath Group 3 Reagent kit and SpeI [9].
Restriction digestion was performed with SmaI (Bio-
Rad Laboratories). For PFGE interpretation the cri-
teria described by Tenover et al. were applied [10].
Different control strains were used: a C. botulinum
isolate carrying the neurotoxin A gene and addition-
ally a C. botulinum strain carrying the neurotoxin B
gene (reference strain REB 89). A C. sporogenes strain
served as control for closely related other Clostridium
species. The S. aureus strain (NCTC 8325) was used as
a culture control with the GenePath Group 1 kit.
RESULTS
Epidemiological investigation
Between 13 October and 5 December 16 cases oc-
curred. After information on the outbreak had been
distributed at local, national, and European level, six
cases which initially had not been notified came
to the attention of the German health authorities.
One patient self-reported following hospitalization
with classical symptoms retrospectively classified as
botulism, but misdiagnosed as a drug overdose. Cases
from outside Germany were not reported.
Of the 16 case-patients 12 were male and four fe-
male. Median age was 33 years (range 20–50 years).
Cases resided in eight different districts of NRW
which are in close proximity to each other (Fig. 1).
Eleven of the cases lived in cities (Cologne, Bonn,
Aachen, Krefeld), the remainder in adjacent rural
districts. The most common symptoms reported were
difficulties in breathing and swallowing [14 cases
(88%) and 9 cases (56%), respectively], and blurred
vision [11 cases (69%)]. Cranial nerve palsy, ptosis,
and palsy of peripheral nerves were observed in nine
(56%), six (38%), and four (25%) cases, respectively.
All patients were hospitalized (median duration 26
days) and recovered fully. Assisted ventilation was
required by five (31%), and administration of anti-
toxin also by five patients. All patients were IDU,
injecting heroin on a regular basis. Twelve reported
injecting drugs subcutaneously and/or intra-
muscularly. The other four denied this route of injec-
tion, but nevertheless clinical examination of their
skin revealed changes (circular scars, swellings, and
redness) which could be due to subcutaneous injection
(‘skin popping’).
Nine cases (six males) were interviewed with the
study questionnaire while the other seven refused
to participate. One of the nine questionnaires was
excluded from analysis because it largely contained
missing or indeterminate answers. Two respondents
answered that they knew about further cases ; how-
ever, they were unable to provide names or addresses
for these persons. No meals or gatherings were at-
tended by two or more patients. Food items known to
bear a risk for transmission of botulism, including
home-bottled or vacuum-packed foods, had not been
consumed recently. Six patients had been using drugs
for a median length of 12 years (range 2–35 years).
Two patients did not specify how long they had used
drugs previously. However, one of them had used
drugs for ‘several years ’ and both indicated that they
had injected at least daily the month before the in-
fection.
The heroin consumed by the patients before onset
of symptoms came from different sources and was
reported to be of different colours (ranging from pale
to dark brown) and consistencies – two patients de-
scribed a black-brown resinous consistency. Five re-
spondents had used dark-coloured heroin within the
4 weeks before symptom onset, whereas the other
three said, that they used ‘normal ’ heroin without
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further specification. A traceback was not poss-
ible. Two patients reported buying heroin in The
Netherlands themselves, and two others had bought
their heroin from dealers who had bought it in The
Netherlands. The other four had recently changed
dealers and did not know the origin of the heroin sold
to them. None of the patients had recently shared
needles or syringes. None had changed their typical
sources of water, acidifying agents (ascorbic acid and
lemon juice) and other ingredients for the preparation
of the drugs.
Laboratory investigation
In six patients C. botulinum were isolated from wound
swabs. In one case bacteria were isolated from dif-
ferent wounds and appeared macroscopically as two
morphologically distinct isolates. However, by PFGE
analysis the strains were indistinguishable. In three
wound swabs, aside from C. botulinum, cultures of
normal skin flora were obtained, i.e. viridans strep-
tococci and coagulase-negative Staphylococcus spp.
From one specimen S. aureus was cultivated. No
other Clostridium spp. were detected. The MIC ranges
(mg/ml) of the C. botulinum strains were: 0.06–0.25
penicillin, 4.0–8.0 clindamycin, 0.5–4.0 piperacillin/
tazobactam, 0.06–0.125 imipenem, and 0.25–4.0
metronidazole.
The neurotoxin B gene was detected by PCR in
all of these strains whereas PCR was negative for
neurotoxin A, E, and F genes. All seven strains in-
vestigated by PFGE exhibited an identical clonal
profile (Fig. 2). In contrast, the two C. botulinum
control strains showed distinct patterns.
Serum samples were obtained for mouse bioassays
from three patients with a positive culture of C. botu-
linum and from additional five patients with either a
negative culture result or without available material
for culture. None of the bioassays were unequivocally
positive.
Only one patient was willing to submit a heroin
sample from his personal stock for testing. A second
sample was obtained from the police. This sample
had been confiscated in Cologne and although it
is unclear whether this sample bears any relation
to the outbreak, both samples were examined but
were repeatedly culture negative for C. botulinum.
Only Propionibacterium spp., Enterococcus spp., and
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Fig. 1. (a) Cases of botulism in injecting drug users (IDUs) by residence and week of onset ; (b) Cases of botulism in IDUs by
week of onset (n=16), Germany, 2005.
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coagulase-negative Staphylococcus spp. could be cul-
tivated.
DISCUSSION
We describe the first outbreak of wound botulism in
Germany. Although the definitive source could not
be determined, the finding of clonality in PFGE
analysis of seven C. botulinum isolates derived from
six patients strongly suggests a common source of the
outbreak. Contaminated heroin seems to be most
probable vehicle since other links between the cases
(such as shared needles or dilution materials) could
not be identified.
The negative culture result of the single heroin
sample obtained from a case does not exclude heroin
as a probable vehicle because street heroin has been
described as having an antibacterial effect and the
number of positive cultures depends on the pre-
analytical preparation methods in the laboratory and
the culture conditions of the heroin samples [11, 12].
In addition, the sample may not be from the same
batch as the heroin at the source of the outbreak.
The investigation of this outbreak was hampered
by legal restrictions concerning the usage of con-
fiscated heroin samples for purposes other than
criminal prosecution. A critical review of this issue
by the district government responsible came to the
conclusion that even heroin confiscated in the context
of a criminal prosecution cannot be readily provided
for other purposes such as microbiological investiga-
tions.
The negative mouse bioassay results of the serum
samples of eight patients might be explained by late
collection of serum samples, although the samples
were collected prior to treatment with antitoxin. This
is known to be an important factor, because the toxin
cannot be detected in serum once it permanently be-
comes bound to its cell receptors [13]. Furthermore,
toxin type A is more aggressive than toxin type B [14].
Thus, the free and unbound amount of toxin present
in the serum was probably below the level of detec-
tion. Toxin testing was positive only for 37% of sera
collected from 309 persons with clinically diagnosed
foodborne botulism reported to CDC from 1975 to
1988 [15]. Critchley et al. reported on 27 patients in
an outbreak of foodborne botulism in North West
England and Wales in 1989. All serological tests of
botulism in the affected patients were negative [16].
On the other hand, a study in the UK showed that
33/88 cases of wound botulism in heroin injectors
(37.5%) reported in the UK and Ireland between
2000 and 2004 were laboratory confirmed by the de-
tection of botulinum neurotoxin in serum [17].
Furthermore, Akbulut et al. reported the detection of
botulinum neurotoxin by bioassay in the sera of 9/16
(56.3%) patients with suspected botulism who were
IDU [18].
In the late 1990s wound botulism had become an
increasing problem in California and subsequently
became apparent elsewhere in the USA [19, 20].
In Europe, an increase of soft-tissue infections with
spore-forming bacteria (Clostridium and Bacillus spp.)
was reported from the UK starting in 2000 [13, 21].
In those reports the disease was linked to IDU in-
jecting drugs by muscle or skin ‘popping’ [21]. In
the USA, the intramuscular or subcutaneous usage
of ‘black tar heroin’ (BTH), a dark, gummy and
frequently impure heroin product primarily from
Mexico and countries south of the USA, was de-
scribed to be particularly associated with wound
botulism [19, 20, 22, 23]. Due to its tarry consistency,
this form of heroin is injected mainly subcutaneously
or intramuscularly which provides excellent environ-
mental conditions for the spores to germinate to
bacteria. BTH does not seem to be the reason for
the increase of disease in the UK since the heroin
distributed in Europe primarily originates from Asia
[24, 25]. However, different forms of heroin may be
injected subcutaneously or intramuscularly, especially
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Fig. 2. PFGE pattern of seven C. botulinum strains isolated
from six patients during the outbreak and control strains.
Lane 12, l-ladder (50–1000 kb) ; lane 11, S. aureus control
strain of the PFGE kit ; lanes 1, 10, C. botulinum control
strains (lane 1, neurotoxin A gene-carrying strain ; lane 10,
neurotoxin B gene-carrying strain) ; lane 3, C. sporogenes ;
lanes 2, 4–9, C. botulinum strains from the six patients.
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by IDU experiencing difficulties in injecting in-
travenously. Acidifying agents required to dissolve
the heroin can cause tissue damage and thus create
favourable conditions for the growth of anaerobic
bacteria.
All of the IDU in this outbreak either reported
subcutaneous or intramuscular injection of heroin
or showed clinical signs of this practice. Five survey
respondents mentioned using heroin which appeared
to them to be of an unusually dark colour. However,
this information could not be verified and therefore
does not allow us to conclude whether this heroin was
actually BTH or not.
Parenteral drug use is well known for carrying the
risk of transmission of several infectious diseases
[26–29]. Wound botulism is of special importance for
two reasons : first, the clinical course is often severe
and life-threatening, and second, the rarity of the
disease renders diagnosis difficult. Furthermore, in
IDU the disease is often misdiagnosed as drug-related
complications, a problem which also occurred in this
outbreak. The correct and timely diagnosis of botu-
lism in IDU is often complicated by multiple health
problems due to malnutrition, poor hygiene and
underlying co-infections. In addition to the harmful
effect on the health of those concerned, the need
for intensive care and treatment costs also have re-
percussions on the health-care system. A greater
awareness of this disease is needed by physicians, as
early diagnosis and prompt therapy are vital for the
reduction of both the risk for death and duration of
hospitalization [30]. If IDU choose to inject drugs
into muscle or skin they should be made aware of
the dangers of wound botulism in order to help detect
the disease early on.
Illicit drug use remains an important issue for
public health authorities in the future [31, 32]. Close
cooperation between public health authorities, street
workers, operators of sheltered injecting facilities, and
medical centres focusing on IDU is essential to es-
tablish a network able to spread information about
newly emerging health threats swiftly and to establish
hazard reduction measures quickly in this high-risk
group for infectious diseases.
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